New data presented at EADV 2026 support stapokibart as a long-term therapeutic option for adolescents with moderate-to-severe AD.

Late-breaking data at EADV 2026 demonstrate durable results over prolonged treatment with lebrikizumab.

Interim Phase 2 data released in an abstract at EADV 2026 showcase findings from a new trispecific antibody, with improved clinical and patient-reported outcomes.

New post hoc data from the LATITUDE-PsO trials demonstrate rapid skin improvement and reduction of key symptoms and everyday QoL burden.

Interim data shared at EADV 2026 showcase a new bispecific antibody that could mean just yearly treatment for patients with psoriasis.

A network meta-analysis presented at EADV 2026 in Vienna showed substantial efficacy for icotrokinra, making it an interesting option for patients with psoriasis.

Results presented at EADV 2026 build on previous findings from the Phase 3 trial of izokibep in HS exploring efficacy across key patient subgroups.

Drainage is an important HS symptom. New data presented at EADV 2026 show how improving drainage can impact QoL, even in those with more severe disease.

New data out to 52 weeks in severe AA were presented at EADV 2026 – revealing continued regrowth beyond active treatment, which offers important proof-of-concept for rezpegaldesleukin.